Critical Contrast: Oncology Pharma (OTCMKTS:ONPH) & Global-E Online (NASDAQ:GLBE)

Oncology Pharma (OTCMKTS:ONPH) and Global-E Online (NASDAQ:GLBE) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Profitability

This table compares Oncology Pharma and Global-E Online’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oncology Pharma	N/A	N/A	N/A
Global-E Online	-10.04%	-8.56%	-6.47%

Risk & Volatility

Oncology Pharma has a beta of 0.73, suggesting that its stock price is 27% less volatile than the S&P 500. Comparatively, Global-E Online has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500.

Insider and Institutional Ownership

94.6% of Global-E Online shares are owned by institutional investors. 18.0% of Oncology Pharma shares are owned by insiders. Comparatively, 11.6% of Global-E Online shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Oncology Pharma and Global-E Online”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Pharma	N/A	N/A	N/A	N/A	N/A
Global-E Online	$752.76 million	9.30	-$133.80 million	($0.44)	-96.86

Oncology Pharma has higher earnings, but lower revenue than Global-E Online.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Oncology Pharma and Global-E Online, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Pharma	0	0	0	0	0.00
Global-E Online	0	1	11	0	2.92

Global-E Online has a consensus target price of $59.58, suggesting a potential upside of 39.80%. Given Global-E Online’s stronger consensus rating and higher possible upside, analysts plainly believe Global-E Online is more favorable than Oncology Pharma.

Summary

Global-E Online beats Oncology Pharma on 6 of the 10 factors compared between the two stocks.

About Oncology Pharma

Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated in 1993 and is based in San Francisco, California.

About Global-E Online

Global-E Online Ltd., together with its subsidiaries, provides a platform to enable and accelerate direct-to-consumer cross-border e-commerce in Israel, the United Kingdom, the United States, and internationally. Its platform enables international shoppers to buy online and merchants to sell from, and to, worldwide. The company was incorporated in 2013 and is headquartered in Petah Tikva, Israel.